Incyte (INCY) Reports Q1 Loss of $2.86, Reaffirms Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/9/2026
- S&P 500, Nasdaq fall as tech selling resumes, Trump vows to respond to downed US helicopter
- Oil prices fall to seven-week low as Iran and Israel halt attacks
- Micron to deliver 'another strong quarter', Goldman says
- Potential implications from SpaceX IPO for Tesla?
- TSMC falls as Taiwan mulls curbs on AI chip exports to China
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- Micron to deliver 'another strong quarter', Goldman says
- UK's Ofcom requires tech firms to create crisis response plans
- Exclusive-SpaceX plans to set IPO price at $135 per share, targeting record $75 billion raise, source says
- Supermicro plans $7 billion financing to fund AI server orders
Incyte Reports 2020 First Quarter Financial Results and Provides Updates on Key Clinical Programs
May 5, 2020 7:00 AM EDTTotal product and royalty revenues of $569 million (+24% vs Q1 2019) for the quarter ended March 31, 2020; Jakafi® (ruxolitinib) revenues of $459 million in Q1 2020 (+22% vs Q1 2019) Pemazyre (pemigatinib) approved by FDA as first targeted treatment for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma Data from successful Phase 3 TRuE-AD program for ruxolitinib cream presented at Revolutionizing Atopic Dermatitis (RAD) conference; NDA on track for end 2020 Ruxolitinib and baricitinib in clinical trials to treat patients suffering from COVID-19
Conference... More
